Volume 7, Number 6—December 2001
Advanced Age a Risk Factor for Illness Temporally Associated with Yellow Fever Vaccination
|Age Years||No. vaccine doses||No. of OAE*a||OAE* reported/ 100,000 doses||RRR (95% CI)||#SyAE*b||SyAE* reported/ 100,000 doses||RRR (95% CI)|
|15-24||189,991||12||6.32||1.8 (0.9-3.5)||2||1.05||3.7 (0.5-26)|
|45-64||442,605||15||3.39||1.0 (0.5-1.8)||5||1.13||4.0 (0.8-20)|
|65-74||86,222||3||3.48||1.0 (0.3-3.2)||3||3.48||12.3 (2.0-73)|
|>75||22,085||2||9.06||2.5 (0.6-10.7)||2||9.06||32 (4.5-226)|
aOAE*= other adverse events (i.e., uncomplicated neurologic or systemic event; hypersensitivity; local reaction) OR systemic adverse events not requiring hospitalization or resulting in death.
bSyAE* = serious systemic adverse events, including only neurologic or multisystemic adverse events requiring hospitalization or resulting in death; this is distinguished from the term SyAE, which indicates all systemic adverse events (See Table 2).
CI = confidence intervals.
1Jeff Altman, University of Washington, Seattle, Washington; Vernon Ansdell, Kaiser Permanente, Honolulu, Hawaii; Elizabeth Barnett, Boston University, Boston, Massachusetts; Michele Barry Yale University, New Haven, Connecticut; Bradley Connor, Cornell University, New York, New York; David Freedman, University of Alabama at Birmingham, Birmingham, Alabama; Alejandra Gurtman, Mount Sinai Medical Center, New York, New York; Elaine Jong, University of Washington, Seattle, Washington; Phyllis Kozarsky, Emory University, Atlanta, Georgia; Russell McMullen, University of Washington, Seattle, Washington; Jan Patterson, University of Texas, San Antonio, Texas; Bradley Sack, Johns Hopkins University, Baltimore, Maryland; Mary E. Wilson, Harvard University, Cambridge, Massachusetts; Martin Wolfe, Traveler's Medical Service of Washington, Washington, D.C.